Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.

Menin is an essential oncogenic cofactor for mixed lineage leukemia 1 (MLL1)-mediated leukemogenesis through its direct interaction with MLL1. Targeting the menin-MLL1 protein-protein interaction represents a promising strategy to block MLL1-mediated leukemogenesis. Employing a structure-based approach and starting from a linear MLL1 octapeptide, we have designed a class of potent macrocyclic peptidomimetic inhibitors of the menin-MLL1 interaction. The most potent macrocyclic peptidomimetic (MCP-1), 34, binds to menin with a K(i) value of 4.7 nM and is >600 times more potent than the corresponding acyclic peptide. Compound 34 is also less peptide-like and has a lower molecular weight than the initial MLL1 peptide. Therefore, compound 34 serves as a promising lead structure for the design of potent and cell-permeable inhibitors of the menin-MLL1 interaction.

[1]  Thomas A Milne,et al.  Interaction of MLL amino terminal sequences with menin is required for transformation. , 2005, Cancer research.

[2]  É. Marsault,et al.  Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.

[3]  Maksymilian Chruszcz,et al.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.

[4]  M. Krzywinski,et al.  New insights to the MLL recombinome of acute leukemias , 2009, Leukemia.

[5]  Shaomeng Wang,et al.  Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors. , 2012, ACS medicinal chemistry letters.

[6]  Jolanta Grembecka,et al.  Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction , 2010, The Journal of Biological Chemistry.

[7]  Xueliang Fang,et al.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. , 2004, Analytical biochemistry.

[8]  Ya-Xiong Chen,et al.  The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Shaomeng Wang,et al.  Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation. , 2011, ACS medicinal chemistry letters.

[10]  Shaomeng Wang,et al.  Computational analysis of protein hotspots. , 2010, ACS medicinal chemistry letters.

[11]  P. Kollman,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000 .

[12]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[13]  Helen E Blackwell,et al.  Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis. , 1998, Angewandte Chemie.

[14]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[15]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[16]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[17]  T. Rabbitts,et al.  Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. , 2004, Genes & development.

[18]  M. Lei,et al.  The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.